Washington Report

Mar 01, 2013
Pharmaceutical Executive
Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.
Feb 01, 2013
Pharmaceutical Executive
More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.
Jan 01, 2013
Pharmaceutical Executive
FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
Dec 01, 2012
Pharmaceutical Executive
Tax and budget decisions will shape the healthcare market and drug research and regulation.
Nov 01, 2012
Pharmaceutical Executive
While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.
Oct 01, 2012
Pharmaceutical Executive
New fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.
Sep 01, 2012
Pharmaceutical Executive
Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
Aug 01, 2012
Pharmaceutical Executive
Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" -fee renewal legislation.
Jul 01, 2012
Pharmaceutical Executive
Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports.
Jun 01, 2012
Pharmaceutical Executive
A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
cialis generika preisvergleich

read more

lorem ipsum